Equine/Horse encephalitis virus/Eastern and Western EE virus Glycoproteins E1 antibody and antigen (recombinant protein)

 Download 

Diagnostic anti-Equine/Horse encephalitis virus/Eastern and Western EE virus Glycoproteins E1 antibodies pairs and antigen for animal health (animal Equine/Horse infectious disease Eastern Equine/Horse encephalitis (EEE), western Equine/Horse encephalitis (WEE) and Venezuelan Equine/Horse encephalitis (VEE)) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT

Go to Equine/Horse disease testing products collection >>

Product information

Catalog No.	Description	US $ Price (per mg)
GMP-VT-P147-Tg001-Ag01	Recombinant Equine/Horse encephalitis virus/Eastern and Western EE virus Glycoproteins E1 protein	$3090.00
GMP-VT-P147-Tg001-Ab01	Anti-Equine/Horse encephalitis virus/Eastern and Western EE virus Glycoproteins E1 mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P147-Tg001-Ab02	Anti-Equine/Horse encephalitis virus/Eastern and Western EE virus Glycoproteins E1 mouse monoclonal antibody (mAb)	$3090.00
GMP-VT-P147-Tg001-Ab03	Anti-Equine/Horse encephalitis virus/Eastern and Western EE virus Glycoproteins E1 human monoclonal antibody (mAb)	$3090.00
GMP-VT-P147-Tg001-Ab04	Anti-Equine/Horse encephalitis virus/Eastern and Western EE virus Glycoproteins E1 human monoclonal antibody (mAb)	$3090.00

Size： 1mg | 10mg | 100mg

Product Description

Cat No.	GMP-VT-P147-Tg001-Ag01
Product Name	Recombinant Equine/Horse encephalitis virus/Eastern and Western EE virus Glycoproteins E1 protein
Pathogen	Equine/Horse encephalitis virus/Eastern and Western EE virus
Expression platform	E.coli
Isotypes	Recombinant Antigen
Bioactivity validation	Anti-Equine/Horse encephalitis virus/Eastern and Western EE virus Glycoproteins E1 antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in Equine/Horse encephalitis virus/Eastern and Western EE virus level test of animal Equine/Horse infectious disease with Eastern Equine/Horse encephalitis (EEE), western Equine/Horse encephalitis (WEE) and Venezuelan Equine/Horse encephalitis (VEE).
Tag	His
Product description	Recombinant Equine/Horse encephalitis virus/Eastern and Western EE virus Glycoproteins E1 proteinwas expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P147-Tg001-Ab01,GMP-VT-P147-Tg001-Ab02
Pathogen	Equine/Horse encephalitis virus/Eastern and Western EE virus
Product Name	Anti-Equine/Horse encephalitis virus/Eastern and Western EE virus Glycoproteins E1 mouse monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Mouse IgG
Bioactivity validation	Recombinant Equine/Horse encephalitis virus/Eastern and Western EE virus Glycoproteins E1 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine/Horse encephalitis virus/Eastern and Western EE virus antibodies in Equine/Horse encephalitis virus/Eastern and Western EE virus level test of animal Equine/Horse infectious disease with Eastern Equine/Horse encephalitis (EEE), western Equine/Horse encephalitis (WEE) and Venezuelan Equine/Horse encephalitis (VEE).
Product description	Anti-Equine/Horse encephalitis virus/Eastern and Western EE virus Glycoproteins E1 mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine/Horse encephalitis virus/Eastern and Western EE virus antibodies.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Cat No.	GMP-VT-P147-Tg001-Ab03,GMP-VT-P147-Tg001-Ab04
Pathogen	Equine/Horse encephalitis virus/Eastern and Western EE virus
Product Name	Anti-Equine/Horse encephalitis virus/Eastern and Western EE virus Glycoproteins E1 human monoclonal antibody (mAb)
Expression platform	CHO
Isotypes	Human lgG1
Bioactivity validation	Recombinant Equine/Horse encephalitis virus/Eastern and Western EE virus Glycoproteins E1 antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine/Horse encephalitis virus/Eastern and Western EE virus antibodies in Equine/Horse encephalitis virus/Eastern and Western EE virus level test of animal Equine/Horse infectious disease with Eastern Equine/Horse encephalitis (EEE), western Equine/Horse encephalitis (WEE) and Venezuelan Equine/Horse encephalitis (VEE).
Product description	Anti-Equine/Horse encephalitis virus/Eastern and Western EE virus Glycoproteins E1 mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair.
Purity	Purity: ≥95% (SDS-PAGE)
Application	Paired antibody immunoassay validation in sandwich Elisa, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays.
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference

Validation Data

Click to get more Data / Case study about the product.

Pathogen Information

Equine Encephalitis Virus (EEV) is a devastating pathogen that can cause severe disease and mortality in horses, humans, and other mammals. The virus is transmitted primarily by mosquitoes, which acquire the virus from infected hosts and transmit it to new individuals during blood meals. EEV has two main variants, Eastern Equine Encephalitis Virus (EEEV) and Western Equine Encephalitis Virus (WEEV), which differ in their geographic distribution, pathogenicity, and host range.

EEV belongs to the Togaviridae family of viruses, which includes several important human pathogens such as Chikungunya, Ross River, and the Sindbis virus. EEV is a positive-sense, single-stranded RNA virus that encodes both structural and non-structural proteins. The structural proteins E1 and E2 form the envelope glycoprotein spikes on the surface of the virion, which are responsible for viral entry into host cells and eliciting an immune response. The non-structural proteins, including nsP1, nsP2, nsP3, and nsP4, are involved in viral replication, transcription, and assembly.

EEV has a broad host range and can infect various mammalian species, including horses, birds, rodents, and humans. Among these, horses are considered the most susceptible to EEV infection, and outbreaks of equine encephalitis have been reported regularly in several regions worldwide. Horses infected with EEV can develop severe neurological symptoms, such as ataxia, depression, seizures, and sometimes death. The incidence of EEV infection in humans is much lower than in horses, but when it does occur, it can result in severe disease, particularly in children and elderly individuals. Infection symptoms include headache, fever, nausea, vomiting, dizziness, and signs of encephalitis, such as confusion, disorientation, and seizures.

The diagnosis of EEV infection can be challenging due to the similarity of symptoms with other neuroinvasive diseases and the lack of specific antiviral treatments. Therefore, accurate and timely diagnosis is essential for the implementation of effective public health measures to control the spread of EEV. Serological assays, viral isolation, and nucleic acid amplification tests are the most commonly used diagnostic methods for EEV detection. Serological assays, such as ELISA or neutralization assays, detect the presence of antibodies against viral antigens in serum or cerebrospinal fluid samples and are useful for confirming past exposure to the virus or monitoring vaccine efficacy. Viral isolation involves culturing the virus in cell culture, followed by identification and characterization of the isolated virus by serology or genetic sequencing. Nucleic acid amplification tests, such as PCR or RT-PCR, detect viral RNA in blood or tissue samples and provide a more rapid and sensitive method of virus detection than serology or culture. The use of specific primer sets targeting conserved regions of the E1 or E2 genes or the nsP2 and nsP4 non-structural proteins can provide highly specific and sensitive results.

In addition to diagnostic methods, preventive measures such as vaccination and vector control are critical for reducing the incidence and severity of EEV infection. Several vaccines are available for horses, which have been shown to provide significant protection against EEV infection, especially when combined with vector control measures such as mosquito control and screening of incoming horses. For humans, no licensed vaccines are available, and prevention primarily depends on avoiding exposure to mosquito bites, using insect repellents, and wearing protective clothing.

In conclusion, EEV is an important pathogen that causes severe disease and mortality in both horses and humans. The development of accurate and timely diagnostic methods and effective prevention strategies is crucial for controlling the spread of EEV and reducing its impact on public health and the equine industry.

About GDU